Biological assessment of triazine dendrimer: Toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct

Molecular Pharmaceutics

Volumn 7, Issue 4, 2010, Pages 993-1006

  Lo, Su Tang ^a   Stern, Stephan ^b   Clogston, Jeffrey D ^b   Zheng, Jiwen ^b   Adiseshaiah, Pavan P ^b   Dobrovolskaia, Marina ^b   Lim, Jongdoo ^c   Patri, Anil K ^b   Sun, Xiankai ^a   Simanek, Eric E ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b SAIC FREDERICK INC   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

colon cancer; dendrimer; Drug delivery; in vivo; melamine; paclitaxel; prostate cancer; therapy; triazine

Indexed keywords

DENDRIMER; PACLITAXEL; TRIAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT SCATTERING; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; THROMBOCYTE AGGREGATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE; CELL LINE, TUMOR; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; DENDRIMERS; FRACTIONATION, FIELD FLOW; HEP G2 CELLS; HUMANS; MALE; MICE; MICE, SCID; MODELS, CHEMICAL; MOLECULAR WEIGHT; PACLITAXEL; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; RATS; SWINE; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955247075     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100104x     Document Type: Article

References (45)

1. Scripture, C. D.; Figg, W. D.; Sparreboom, A. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy Ther. Clin. Risk Manage. 2005, 1, 107-114
2. Crown, J.; O'Leary, M.; Ooi, W. S. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience Oncologist 2004, 9, 24-32
3. Singla, A. K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations Int. J. Pharm. 2002, 235, 179-192
4. Duncan, R. The dawning era of polymer therapeutics Nat. Rev. Drug Discovery 2003, 2, 347-360
5. Putnam, D. Drug delivery: the heart of the matter Nat. Mater. 2008, 7, 836-837
6. Aulenta, F.; Hayes, W.; Rannard, S. Dendrimers: a new class of nanoscopic containers and delivery devices Eur. Polym. J. 2003, 39, 1741-1771
7. Haag, R.; Kratz, F. Polymer therapeutics: Concepts and applications Angew. Chem., Int. Ed. 2006, 45, 1198-1215
8. Esfand, R.; Tomalia, D. A. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications Drug Discovery Today 2001, 6, 427-436
9. Menjoge, A. R.; Kannan, R. M.; Tomalia, D. A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications Drug Discovery Today 2010, 15, 171-185
10. Boas, U.; Heegaard, P. M. H. Dendrimers in drug research Chem. Soc. Rev. 2004, 33, 43-63
11. Svenson, S. Dendrimers as versatile platform in drug delivery applications Eur. J. Pharm. Biopharm. 2009, 71, 445-462
12. Myc, A.; Douce, Thomas B.; Ahuja, N.; Kotlyar, A.; Kukowska-Latallo, J.; Thomas, T. P.; Baker, J. R., Jr. Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates Anti-Cancer Drugs 2008, 19, 143-149
13. Fox, M. E.; Guillaudeu, S.; Fréchet, J. M. J.; Jerger, K.; Macaraeg, N.; Szoka, F. C. Synthesis and in vivo antitumor efficacy of PEGylated poly(l -lysine) dendrimer-camptothecin conjugates Mol. Pharmaceutics 2009, 6, 1562-1572
14. Lee, C. C.; Gillies, E. R.; Fox, M. E.; Guillaudeu, S. J.; Frechet, J. M. J.; Dy, E. E.; Szoka, F. C. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 16649-16654
15. Kaminskas, L. M.; Kelly, B. D.; McLeod, V. M.; Boyd, B. J.; Krippner, G. Y.; Williams, E. D.; Porter, C. J. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers Mol. Pharmaceutics 2009, 6, 1190-1204
16. Simanek, E. E.; Hanan, A.; Lalwani, S.; Lim, J.; Mintzer, M.; Venditto, V. J.; Vittur, B. The eight year thicket of triazine dendrimers: strategies, targets, and applications Proc. R. Soc. A 2010, 466, 1445-1468
17. Chouai, A.; Simanek, E. E. Kilogram-scale synthesis of a second generation dendrimer based on 1,3,5-triazine using green and industrially compatible methods with a single chromatographic step J. Org. Chem. 2008, 73, 2357-2366
18. Steffensen, M. B.; Simanek, E. E. Synthesis and manipulation of orthogonally protected dendrimers: Building blocks for library synthesis Angew. Chem., Int. Ed. 2004, 43, 5178-5180
19. Lim, J.; Simanek, E. E. Synthesis of water-soluble dendrimers based on melamine bearing 16 paclitaxel groups Org. Lett. 2008, 10, 201-204
20. Lim, J.; Chouai, A.; Lo, S.-T.; Liu, W.; Sun, X.; Simanek, E. E. Design, synthesis, characterization, and biological evaluation of triazine dendrimers bearing paclitaxel using ester and ester/disulfide linkages Biconjugate Chem. 2009, 20, 2154-2161
21. Venditto, V. J.; Allred, K.; Allred, C. D.; Simanek, E. E. Intercepting triazine dendrimer synthesis with nucleophilic pharmacophores as a general strategy toward drug delivery vehicles Chem. Commun. 2009, 5541-5542
22. Neerman, M. F.; Zhang, W.; Parrish, A. R.; Simanek, E. E. In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery Int. J. Pharm. 2004, 281, 129-132
23. Chen, H. T.; Neerman, M. F.; Parrish, A. R.; Simanek, E. E. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery J. Am. Chem. Soc. 2004, 126, 10044-10048
24. Neerman, M. F.; Umali, A. P.; Chen, H.-T.; Waghela, S. D.; Parrish, A. R.; Simanek, E. E. Biological evaluation of dendrimers based on melamines J. Drug Delivery Sci. Technol. 2005, 15, 31-40
25. Zhang, W.; Jiang, J.; Qin, C.; Pérez, L. M.; Parrish, A. R.; Safe, S. H.; Simanek, E. E. Triazine dendrimers for drug delivery: evaluation of solubilization properties, activity in cell culture, and in vivo toxicity of a candidate vehicle Supramol. Chem. 2003, 15, 607-616
26. Lim, J.; Guo, Y.; Rostollan, C. L.; Stanfield, J.; Hsieh, J.-T.; Sun, X.; Simanek, E. E. The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers Mol. Pharmaceutics 2008, 5, 540-547
27. Zhang, W.; Gonzalez, S. O.; Simanek, E. E. Structure-activity relationships in dendrimers based on triazines: Gelation depends on choice of linking and surface groups Macromolecules 2002, 35, 9015-9021
28. Mullen, D. G.; Fang, M.; Desai, A.; Baker, J. R., Jr.; Orr, B. G.; Holl, M. B. B. A Quantitative Assessment of Nanoparticle-Ligand Distributions: Implications for Targeted Drug and Imaging Delivery in Dendrimer Conjugates ACS Nano 2010, 4, 657-670
29. Weigel, T. L.; Lotze, M. T.; Kim, P. K.; Amoscato, A. A.; Luketich, J. D.; Odoux, C. Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity J. Thorac. Cardiovasc. Surg. 2000, 119, 795-803
30. Tomalia, D. A.; Reyna, L. A.; Svenson, S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging Biochem. Soc. Trans. 2007, 35, 61-67 2007
31. Kobayashi, H.; Brechbiel, M. W. Mol. Imaging 2003, 2, 1-10
32. Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A.; Tao, C.; De, T.; Beals, B.; Dykes, D.; Noker, P.; Yao, R.; Labao, E.; Hawkins, M.; Soon-Shiong, P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin. Cancer Res. 2006, 12, 1317-1324
33. Klerk, C. P. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals Biotechniques 2007, 43 (1 Suppl.) 7-13
34. Feng, Z.; Zhao, G.; Yu, L.; Gough, D.; Howell, S. B. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane Cancer Chemother. Pharmacol. 2010, 65, 923-30
35. Albain, K. S.; Belani, C. P.; Bonomi, P.; O'Byrne, K. J.; Schiller, J. H.; Socinski, M. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel inchemotherapy-naive women with advanced-stage non-small-celllung cancer and performance status of 2 Clin. Lung Cancer 2006, 7, 417-419
36. Beeram, M.; Rowinsky, E. K.; Hammond, L. A.; Patnaik, A.; Schwartz, G. H.; de Bono, J. S.; Forero, L.; Forouzesh, B.; Berg, K. E.; Rubin, E. H.; Beers, S.; Killian, A.; Kwiatek, J.; McGuire, J.; Spivey, L.; Takimoto, C. H. A phase I pharmacokinetic(PK) study of PEG-paclitaxel in patients with advanced solid tumors Proc. Am. Soc. Clin. Oncol. 2002, 21, 405
37. Meerum Terwogt, J. M.; ten Bokkel Huinink, W. W.; Schellens, J. H.; Schot, M.; Mandjes, I. A.; Zurlo, M. G.; Rocchetti, M.; Rosing, H.; Koopman, F. J.; Beijnen, J. H. Phase I clinical and pharmacokinetic study of PNU166945,a novel water-soluble polymer-conjugated prodrug of paclitaxel Anticancer Drugs 2001, 12, 315-323
38. Khandare, J. J.; Jayant, S.; Singh, A.; Chandna, P.; Wang, Y.; Vorsa, N.; Minko, T. Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel Bioconjugate Chem. 2006, 17, 1464-1472
39. Gao, Y.; Chen, L.; Gu, W.; Xi, Y.; Lin, L.; Li, Y. Targeted nanoassembly loaded with docetaxel improves intracellular drug delivery and efficacy in murine breast cancer model Mol. Pharmaceutics 2008, 5, 1044-1054
40. Vrudhula, V. M.; MacMaster, J. F.; Li, Z.; Kerr, D. E.; Senter, P. D. Reductively activated disulfide prodrugs of paclitaxel Bioorg. Med. Chem. Lett. 2002, 12, 3591-3594
41. Majoros, I. J.; Myc, A.; Thomas, T.; Mehta, C. B.; Baker, J. R. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality Biomacromolecules 2006, 7, 572-579
42. Papas, S.; Akoumianaki, T.; Kalogios, C.; Hadjiarapolglou, L.; Theodoropoulous, P. A.; Tsikaris, V. Synthesis and antitumor activity of peptide-paclitaxel conjugates J. Pept. Sci. 2007, 13, 662-671
43. El Alaoui, A.; Saha, N.; Schmidt, F.; Monneret, C.; Florent, J.-C. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy Bioorg. Med. Chem. Lett. 2006, 14, 5012-5019
44. Zou, Y.; Fu, H.; Ghosh, S.; Farquhar, D.; Klostergaard, J. Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic nonsmall cell lung cancer xenograft models Clin. Cancer Res. 2004, 10, 7382-7391
45. Guillemard, V.; Saragovi, H. U. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity Cancer Res. 2001, 61, 694-699